Modulating cholesterol efflux capacity to improve cardiovascular disease
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Purpose of review: Low HDL-cholesterol (HDL-C) levels are predictive of incident atherosclerotic cardiovascular disease events. However, the use of medication to raise HDL-C levels has not consistently shown clinical benefit. As a result, studies have shifted toward HDL function, specifically cholesterol efflux, which has been inversely associated with prevalent subclinical atherosclerosis as well as subsequent atherosclerotic cardiovascular disease events. The purpose of this review is to summarize the effects of current medications and interventions on cholesterol efflux capacity. Recent findings: Medications for cardiovascular health, including statins, fibrates, niacin, and novel therapeutics, are reviewed for their effect on cholesterol efflux. Differences in population studied and assay used are addressed appropriately. Lifestyle interventions, including diet and exercise, are also included in the review. Summary: The modification of cholesterol efflux capacity (CEC) by current medications and interventions has been investigated in both large randomized control trials and smaller observational cohorts. This review serves to compile the results of these studies and evaluate CEC modulation by commonly used medications. Altering CEC could be a novel therapeutic approach to improving cardiovascular risk profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943 · cited 1×
“In light of this information, one subset of a large randomized control trial studied patients with metabolic syndrome who were treated with pioglitazone [15].”
BackgroundEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“A similar result was found in the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events trial, in which high-risk participants were randomized to either niacin and laropiprant or a placebo in addition to ongoing statin therapy [5].”
ResultHDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Self-citationCholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953
HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Yvan-Charvet, L., Ranalletta, M., Wang, N., Han, S., Terasaka, N., Li, R., Welch, C., & Tall, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33372 · Cited by 536
Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu171 · Cited by 251 · cited 1×
“com acute coronary syndrome treated with CER-001 did not have any change in atheroma volume or coronary artery calcium score [54].”
BackgroundHernáez, Á., Fernández-Castillejo, S., Farràs, M., Catalán, Ú., Subirana, I., Montes, R., Solà, R., Muñoz-Aguayo, D., Gelabert-Gorgues, A., Díaz-Gil, Ó., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303374 · Cited by 150
Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients
Franceschini, G., Calabresi, L., Colombo, C., Favari, E., Bernini, F., & Sirtori, C. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.10.017 · Cited by 66 · cited 2×
“In contrast, a study of fenofibrate revealed no change in SRB1-mediated CEC but an increase in ABCA1-mediated CEC [23].”
BackgroundResult
Cited by
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Determinants of cholesterol efflux capacity in humans
Talbot, C. P. J., Plat, J., Ritsch, A., & Mensink, R. P. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.12.001 · Cited by 99
Rader, D. J. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2168 · Cited by 32
Mediterranean Approach to Improving High-Density Lipoprotein Function
Rader, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.026278 · Cited by 7
Metadata
- Authors
- Brownell, N., & Rohatgi, A.
- Venue
- Current Opinion in Lipidology
- Published
- 2016-08
- Volume
- 27
- Issue
- 4
- Pages
- 398-407
- ISSN
- 0957-9672 (ISSN-L)
- 1473-6535
- OpenAlex
- W2398353187
- Cited by
- 45
- References
- 10
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulating cholesterol efflux capacity to improve cardiovascular disease. https://app.cochat.ai/papers/10.1097/mol.0000000000000317
- The paper
- Brownell, N., & Rohatgi, A. (2016). Modulating cholesterol efflux capacity to improve cardiovascular disease. Current Opinion in Lipidology. https://doi.org/10.1097/mol.0000000000000317
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.